» Articles » PMID: 20698574

Vaccine Delivery by Polymeric Vehicles in the Mouse Reproductive Tract Induces Sustained Local and Systemic Immunity

Overview
Journal Mol Pharm
Specialty Pharmacology
Date 2010 Aug 12
PMID 20698574
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Design of easily administered vaccines to protect the female reproductive tract against STIs such as HIV, HPV and HSV is a major step in improving world health standards. However, the effect of immunization routes and regimens (prime/boost) on immune response is not well-understood. Here, we present a systematic study of vaccine delivery by different routes and prime/boosting regimens to produce a robust humoral immune response in the reproductive tract. A model antigen, ovalbumin (OVA), was delivered orally or intranasally via polymer particles, and intravaginally via polymer disks to female mice. Repeated prime/boost at a single site result in high OVA-specific antibody levels in the serum for mice immunized orally (IgA) and invaginally (IgA and IgG) after 3 months. Vaginal antibody titers were the highest for mice immunized by intravaginal routes. Vaginal boosting following intranasal or oral priming did not appear to offer similar advantages to those primed intravaginally. Systemic immunization with OVA in Freund's adjuvant produced robust serum IgG levels, but little serum IgA or antibodies in the vaginal washings. All immunization schemes produced a significant level of IgG in the intestinal mucosa, with the exception of nasal priming followed by intravaginal boost with slow-releasing disks. In contrast, only immunization by nasal priming and intravaginal boost with fast-releasing disks was able to achieve significantly high intestinal IgA titers.

Citing Articles

Biodistribution of Polymeric Nanoparticles following in utero Delivery to a Nonhuman Primate.

Eaton D, Lynn A, Surprenant J, Deschenes E, Guerra M, Rivero R Biomed Hub. 2025; 10(1):23-32.

PMID: 39845408 PMC: 11753793. DOI: 10.1159/000543138.


Vaginal delivery of vaccines.

VanBenschoten H, Woodrow K Adv Drug Deliv Rev. 2021; 178:113956.

PMID: 34481031 PMC: 8722700. DOI: 10.1016/j.addr.2021.113956.


Recent Advances in Polymer-Based Vaginal Drug Delivery Systems.

Osmalek T, Froelich A, Jadach B, Tatarek A, Gadzinski P, Falana A Pharmaceutics. 2021; 13(6).

PMID: 34203714 PMC: 8232205. DOI: 10.3390/pharmaceutics13060884.


Demystifying particle-based oral vaccines.

Gonzalez-Cruz P, Gill H Expert Opin Drug Deliv. 2021; 18(10):1455-1472.

PMID: 34148474 PMC: 8590737. DOI: 10.1080/17425247.2021.1946511.


Polymeric Biomaterials: Diverse Functions Enabled by Advances in Macromolecular Chemistry.

Liang Y, Li L, Scott R, Kiick K Macromolecules. 2017; 50(2):483-502.

PMID: 29151616 PMC: 5687278. DOI: 10.1021/acs.macromol.6b02389.


References
1.
Fattal E, Pecquet S, Trolle S, Chachaty E, Couvreur P, Andremont A . Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D,L-lactide-co-glycolide) microspheres. Vaccine. 1998; 16(7):685-91. DOI: 10.1016/s0264-410x(97)00261-2. View

2.
Luci C, Hervouet C, Rousseau D, Holmgren J, Czerkinsky C, Anjuere F . Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin. J Immunol. 2006; 176(5):2749-57. DOI: 10.4049/jimmunol.176.5.2749. View

3.
Tabata Y, Inoue Y, Ikada Y . Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine. 1996; 14(17-18):1677-85. DOI: 10.1016/s0264-410x(96)00149-1. View

4.
Kato H, Bukawa H, Hagiwara E, Xin K, Hamajima K, Kawamoto S . Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses. Vaccine. 2000; 18(13):1151-60. DOI: 10.1016/s0264-410x(99)00385-0. View

5.
Tengvall S, OHagan D, Harandi A . Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88. Antiviral Res. 2008; 78(3):202-14. DOI: 10.1016/j.antiviral.2007.12.014. View